Skip to main content
Clinical Trials/NCT02934646
NCT02934646
Completed
Phase 2

Clinical Validation of a Powered Exoskeleton for the Treatment of Elbow Spasticity: Phase II Study

Auxilium Vitae Volterra0 sites20 target enrollmentJuly 2014

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Muscle Spasticity
Sponsor
Auxilium Vitae Volterra
Enrollment
20
Primary Endpoint
Modified Ashworth Scale
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

This is a phase-II clinical study to assess whether intense passive mobilization of the elbow during the early stage is effective in preventing spasticity from occurring at a later stage. A group of subacute stroke patients was treated with the device named NEUROExos Elbow Module (NEEM) on a daily basis, in addition to traditional physical therapy. The outcome was assessed in terms of (i) system safety, (ii) system usability and (iii) treatment efficacy.

Investigators expected that intense therapy performed in the sub-acute phase following the stroke would be effective in preventing elbow spasticity from occurring at a later stage (i.e. 3-4 months after the stroke), the latter being quantified by means of the Modified Ashworth Scale (MAS). Similarly to other phase-II studies in the field of post-stroke rehabilitation, the present study will include only one group of patients. As a secondary objective, similarly to other studies with robot-assisted therapy, investigators wiil test the ability of this system to be used for assessing rehabilitation outcome. Investigators will introduce novel evaluation metrics based on the kinematics and kinetics variables recorded by the NEEM and compared them with MAS values.

Registry
clinicaltrials.gov
Start Date
July 2014
End Date
July 2016
Last Updated
7 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Auxilium Vitae Volterra
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Upper limb spasticity due to neurological impairment;
  • Cognitive abilities sufficient for understanding instructions;
  • Absence of severe pain assessed as Visual Analogic Score (VAS) \< 4 (range 0-10).

Exclusion Criteria

  • Unstable general clinical conditions;
  • Unability to keep sitting posture;
  • Tendon retractions limiting upper limb joints range of motion.

Outcomes

Primary Outcomes

Modified Ashworth Scale

Time Frame: 2 weeks

Impairmente level maesure according to ICF

Secondary Outcomes

  • Maximum Extension Torque(2 weeks)
  • Zero-Torque Angle(2 weeks)
  • Range of Motion(2 weeks)

Similar Trials